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Introduction
The common variable immunodeficiency (CVID) is 
a primary immunodeficiency of humoral immunity with 
heterogeneous clinical symptoms. The clinical symptoms 
typical for CVID are frequent, recurrent infections with 
poor response to therapy. The laboratory tests showed hy-
pogammaglobulinaemia (IgG only, IgG plus IgA and/or 
IgM), low production of specific antibodies in response 
to vaccines, and disorders of cellular immunity. The typi-
cal therapy for CVID includes the replacement of specific 
antibodies with human immunoglobulin substitution in in-
travenous (IVIG) or subcutaneous form (SCIG), standard 
dose 0.4-0.6 g/kg body weight/month, prophylaxis, and 
symptomatic therapy of infections [1-8]. Common vari-
able immunodeficiency is associated with autoimmunity 
in about 30% of patients. Most common of all autoimmune 
diseases in CVID are cytopaenias, including thrombocyto-
paenia. In children, gastrointestinal autoimmune diseases 
(e.g. celiac disease) are noted very often, while systemic 
autoimmune diseases, including rheumatoid arthritis, are 
observed in adults [3-6, 8-10]. In half of patients with 
CVID and autoimmune diseases, especially cytopaenias, 
this autoimmunity occurs prior to diagnosis of immunode-
ficiency [6, 7, 10].
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Abstract
Common variable immunodeficiency (CVID) is a primary immunodeficiency of humoral immunity 
with heterogeneous clinical features. Diagnosis of CVID is based on hypogammaglobulinaemia, low 
production of specific antibodies, and disorders of cellular immunity. The standard therapy includes 
replacement of specific antibodies with human immunoglobulin, prophylaxis, and symptomatic therapy 
of infections. High prevalence of autoimmunity is characteristic for CVID, most commonly: thrombo-
cytopaenia and neutropaenia, celiac disease, and systemic autoimmune diseases.
The study included seven children diagnosed with CVID and treated with immunoglobulin substi-
tution from 2 to 12 years. Thrombocytopenia was diagnosed prior to CVID in four children, developed 
during immunoglobulin substitution in three children. In one boy with CVID and thrombocytopaenia, 
haemolytic anaemia occurred, so a diagnosis of Evans syndrome was established. Therapy of thrombo-
cytopaenia previous to CVID included steroids and/or immunoglobulins in high dose, and azathioprine. 
In children with CVID on regular immunoglobulin substitution, episodes of acute thrombocytopaenia 
were associated with infections and were treated with high doses of immunoglobulins and steroids. In 
two patients only chronic thrombocytopaenia was noted. Splenectomy was necessary in one patient 
because of severe course of thrombocytopaenia.
The results of the study indicated a supportive role of regular immunoglobulin substitution in pa-
tients with CVID and chronic thrombocytopaenia. However, regular substitution of immunoglobulins in 
CVID patients did not prevent the occurrence of autoimmune thrombocytopaenia episodes or exacerba-
tions of chronic form. In episodes of acute thrombocytopaenia or exacerbations of chronic thrombocy-
topaenia, infusions of immunoglobulins in high dose are effective, despite previous regular substitution 
in the replacing dose.
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The cause of prevalence and pathomechanisms of au-
toimmunity in primary humoral immune deficiency, e.g. 
hyper IgM syndrome, X-linked agammaglobulinaemia, 
IgA deficiency, and CVID, are not well understood and 
different hypotheses have been suggested [4, 6, 8-10]. 
Moreover, the differences of autoimmune disease profiles 
between children and adults, and the different types of au-
toimmune diseases in a given humoral immune deficiency, 
are open questions. The association between total anterior 
circulation infarct (TACI) deficiency and higher frequency 
of autoimmune disease in CVID suggest the role of this 
particular genetic mutation in the autoimmune process. 
One of the possible explanations is that the partial TACI 
signal in the heterogeneous state may support the survival 
of autoreactive B cells. However, autoimmune diseases are 
noted in CVID patients without TACI deficiency [4, 8]. 
The common observation of reduced number of switched 
memory B cells (CD27+) and expansion of activated CD-
21low B cells containing a high proportion of autoreactive 
B cells are connected with another mechanism leading to 
autoimmunity [4, 6, 8]. Moreover, the survival of auto-
reactive B cells is supported by B cell activating factor 
(BAFF) and acidic protein rich in leucine (APRIL) noted 
at high levels in CVID patients with autoimmunity [4, 8]. 
Besides the disturbances in B cell maturation and activa-
tion, T lymphocytes are also involved in the development 
of autoimmunity in CVID. The decrease of T regulatory 
number (CD4+, CD25+, Foxp3+) is indicated as factor 
facilitating the autoimmune process [4, 6, 8, 9]. In the sub-
group of CVID patients with lymphopaenia, an increased 
level of interleukin-7 (IL-7) was found, and the role of this 
cytokine in the expansion of autoreactive T cell clones was 
included into the mechanisms of autoimmunity in these 
patients [8].
Standard therapy of acute and chronic thrombocy-
topaenia in CVID patients is based on steroids in high 
doses, followed prolong therapy with maintenance doses 
and immunoglobulins. The intravenous infusion of high 
doses of immunoglobulins (1.0-2.0 g/kg body weight) 
are effective in increasing platelet numbers; however, 
a long-lasting effect is noted only in some CVID pa-
tients. This therapy with high doses of immunoglobulins 
in acute thrombocytopaenia episodes is more effective in 
patients without CVID [7, 11]. Moreover, in the clinical 
course of thrombocytopaenia in CVID patients, resis-
tance to therapy is noted, suggesting active autoimmune 
process, despite regular immunoglobulin substitutions 
in replacement doses. This amount of immunoglobulins 
seemed to be too low to show anti-autoimmune mecha-
nisms active when high dose was used. However, this low 
dose of immunoglobulins was able to stimulate dendritic 
cell maturation, which was shown in agammaglobuli-
naemia patients with defective dendritic cell phenotypes 
[5]. A similar defective phenotype of dendritic cells was 
found in CVID patients. This observation is important 
for the autoimmune process because dendritic cells play 
a critical role in predisposition to several pathological 
conditions, including autoimmunity. Stimulation of den-
dritic cell maturation might prevent the autoimmunity 
predisposition associated with the defective function of 
these cells in immunodeficient patients. It is believed that 
regular substitution of immunoglobulins, even in a re-
placing dose, restores phenotypes and normal function of 
dendritic cells in immunodeficiency [5]. In CVID patients 
with refractory thrombocytopaenia, recurrent episodes of 
exacerbations, or chronic thrombocytopaenia, second-line 
therapy with immunosuppressive drugs like azathioprine, 
vincristine, cyclophosphamide, and splenectomy is used 
[7, 10, 11]. Splenectomy is effective in these patients, 
similarly to patients without immunodeficiency, and safe 
without higher risk of severe infections in immunodefi-
ciency [11]. The use of rituximab in CVID patients with 
a normal number of B cells and severe autoimmunity 
symptoms seemed to be another therapeutic proposition 
[11, 13], but regular substitution of immunoglobulins is 
indicated because of increased risk of severe infections 
[4, 7, 11, 13].
Aim of the study
Observations of thrombocytopaenia in patients with 
CVID and the effect of regular substitution of immuno-
globulins in replacing dose.
Material and methods
Patients
The study included 7 patients (six boys, one girl) di-
agnosed as CVID (Table 1) based on hypogammaglobu-
linaemia (IgG, IgG/IgA, IgG/IgM), low level of specific 
antibodies and disturbances of cellular immunity (reverse 
CD4 : CD8 ratio), and poor response of lymphocytes to 
stimulation with mitogens (PHA, PWM) and antigens 
(CD3, PPD and Candida).
The clinical symptoms included recurrent infections 
(mainly in the respiratory tract), pneumonias, otitis, and 
sinusitis in older children. Following diagnosis of CVID, 
all patients were treated with regular immunoglobulin 
substitution (every month, intravenously) in a replacing 
dose (0.4-0.6 g/kg body weight). The thrombocytopaenia 
was diagnosed before diagnosis of CVID in four patients, 
and after CVID diagnosis in the remaining three patients 
(Table 2).
Thrombocytopaenia prior to diagnosis of CVID was 
treated with high doses of IVIG and/or steroids (high dose 
pulses) when the IVIG effect was short lasting. One pa-
tient underwent splenectomy followed by a high and sta-
ble number of platelets, which excluded this patient from 
further observation.
Central European Journal of Immunology 2015; 40(1)
Thrombocytopenia in common variable immunodeficiency patients – clinical course, management, and effect of immunoglobulins
85
T
ab
le
 1
. C
ha
ra
ct
er
is
tic
s 
an
d 
co
ur
se
 o
f 
co
m
m
on
 v
ar
ia
bl
e 
im
m
un
od
ef
ic
ie
nc
y 
(C
V
ID
) 
in
 th
e 
st
ud
ie
d 
pa
tie
nt
s
P
at
ie
nt
 n
um
be
r
1
2
3
4
5
6
7
A
ge
 o
f 
di
ag
no
si
s:
 
C
V
ID
6 
ye
ar
s
8 
ye
ar
s
3 
ye
ar
s 
6 
m
on
th
s
12
 y
ea
rs
10
 y
ea
rs
8 
ye
ar
s
5 
ye
ar
s
M
ai
n 
sy
m
pt
om
s 
of
 C
V
ID
in
fe
ct
io
ns
 o
f 
re
sp
ir
at
or
y 
tr
ac
t, 
ly
m
ph
ad
en
op
at
hy
 
sp
le
no
m
eg
al
y
th
ro
m
bo
cy
to
pa
en
ia
 
sp
le
no
m
eg
al
y
se
ve
re
 
th
ro
m
bo
cy
to
pe
ni
a 
ly
m
ph
ad
en
op
at
hy
 
sp
le
no
m
eg
al
y
th
ro
m
bo
cy
to
pa
en
ia
 
le
uk
op
ae
ni
a
th
ro
m
bo
cy
to
pa
en
ia
th
ro
m
bo
cy
to
pa
en
ia
pn
eu
m
on
ia
s 
ly
m
ph
ad
en
op
at
hy
, 
sp
le
no
m
eg
al
y
L
ab
or
at
or
y 
da
ta
 
at
 d
ia
gn
os
is
 
of
 C
V
ID
lo
w
 le
ve
l o
f 
Ig
G
 I
gA
, l
ow
 
nu
m
be
r 
of
 T
 c
el
ls
, r
ev
er
se
 
C
D
4:
C
D
8 
ra
tio
, w
ea
k 
re
sp
on
se
 to
 v
ac
ci
ne
s
lo
w
 le
ve
l o
f 
Ig
G
, I
gA
, 
Ig
M
, l
ow
 n
um
be
r 
of
 T
, B
, a
nd
 N
K
 c
el
ls
lo
w
 n
um
be
r 
of
 T
 c
el
ls
, 
la
ck
 o
f 
re
sp
on
se
 T
 c
el
ls
 
to
 s
tim
ul
at
io
n,
 
lo
w
 le
ve
l o
f 
Ig
G
lo
w
 le
ve
l o
f 
Ig
G
, I
gA
 
an
d 
Ig
M
, l
ow
 n
um
be
r 
of
 T
, B
 a
nd
 N
K
 c
el
ls
lo
w
 le
ve
l o
f 
Ig
G
lo
w
 le
ve
l o
f 
Ig
G
, I
gA
lo
w
 le
ve
l o
f 
Ig
G
, 
Ig
M
, l
ac
k 
of
 I
gA
, 
le
uk
op
ae
ni
a,
 w
ea
k 
re
sp
on
se
 to
 v
ac
ci
ne
s
O
th
er
 s
ym
pt
om
s
m
ild
 le
uk
op
ae
ni
a
le
uk
op
ae
ni
a
se
ve
re
 h
ae
m
ol
yt
ic
 
an
ae
m
ia
se
ve
re
 le
uk
op
ae
ni
a
no
no
ag
en
es
is
 o
f 
ki
dn
ey
, 
L
IP
, l
un
g 
fi
br
os
is
 
(p
ro
gr
es
si
on
),
 
br
on
ch
ie
ct
as
es
R
es
po
ns
e 
to
 I
gG
go
od
, n
o 
in
fe
ct
io
ns
go
od
go
od
w
ea
k 
(i
nc
re
as
e 
of
 
pl
at
el
et
s 
2-
3 
da
ys
)
go
od
go
od
w
ea
k 
(l
ow
 le
ve
l 
of
 I
gG
)
C
om
pl
ic
at
io
ns
ad
ve
rs
e 
re
ac
tio
n 
to
 I
V
IG
, s
hi
ft
 
to
 S
C
IG
se
ve
re
 o
st
eo
po
ro
si
s,
 
ov
er
w
ei
gh
t, 
de
la
y 
of
 p
ub
er
ty
O
th
er
 
th
er
ap
ie
s
st
er
oi
ds
 b
ef
or
e
 I
V
IG
st
er
oi
ds
, a
za
th
io
pr
in
e 
pr
ol
on
ge
d 
be
ca
us
e 
of
 lu
ng
 f
ib
ro
si
s 
pr
og
re
ss
io
n
P
re
se
nt
 
st
at
us
SC
IG
IV
IG
, 
L
IP
 d
ia
gn
os
is
no
 s
ub
st
itu
tio
n,
 
he
m
at
ol
og
ic
 c
ar
e
IV
IG
, 
he
m
at
ol
og
ic
 c
ar
e
no
 s
ub
st
itu
tio
n 
no
 s
ym
pt
om
s
no
 s
ub
st
itu
tio
n 
no
 s
ym
pt
om
s
SC
IG
, l
un
gs
 a
nd
 
ki
dn
ey
 in
su
ff
ic
ie
nc
y,
 
sp
le
no
m
eg
al
y
L
IP
 –
 ly
m
ph
oc
yt
e 
in
fi
lt
ra
ti
ng
 p
ne
um
on
ia
, I
V
IG
 –
 in
tr
av
en
ou
s 
su
bs
ti
tu
ti
on
 o
f I
gG
, S
C
IG
 –
 s
ub
cu
ta
ne
ou
s 
fo
rm
 o
f s
ub
st
it
ut
io
n
Central European Journal of Immunology 2015; 40(1)
Anna Pituch-Noworolska et al.
86
T
ab
le
 2
. C
ha
ra
ct
er
is
tic
s 
an
d 
co
ur
se
 o
f 
ch
ro
ni
c 
th
ro
m
bo
cy
to
pa
en
ia
 in
 c
om
m
on
 v
ar
ia
bl
e 
im
m
un
od
ef
ic
ie
nc
y 
(C
V
ID
) 
pa
tie
nt
s
P
at
ie
nt
 n
um
be
r
1
2
3
4
5
6
7
G
en
de
r
bo
y
bo
y
bo
y
gi
rl
bo
y
bo
y
bo
y
A
ge
 o
f 
di
ag
no
si
s:
 
th
ro
m
bo
cy
to
pa
en
ia
14
 y
ea
rs
4 
ye
ar
s
4 
ye
ar
s 
10
 m
on
th
s
8 
ye
ar
s
11
 y
ea
rs
7 
ye
ar
s
13
 y
ea
rs
T
he
ra
py
 
of
 t
hr
om
bo
-
cy
to
pa
en
ia
st
er
oi
ds
 (
pu
ls
es
)
IV
IG
 
1.
0 
g/
kg
 
b.
w
. s
te
ro
id
s,
 
az
at
hi
op
ri
ne
st
er
oi
ds
, a
za
th
io
pr
in
e,
 
IV
IG
 
1.
0 
g/
kg
 b
.w
.
st
er
oi
ds
st
er
oi
ds
, 
IV
IG
 1
.0
 g
/k
g 
b.
w
.
st
er
oi
ds
st
er
oi
ds
C
om
pl
ic
at
io
ns
, 
ot
he
r 
sy
m
pt
om
s
no
no
se
ve
re
 h
ae
m
ol
yt
ic
 
an
ae
m
ia
 
(E
va
ns
 s
yn
dr
om
e)
di
ab
et
es
, s
ev
er
e 
ov
er
w
ei
gh
t
no
no
L
ow
es
t 
nu
m
be
r 
of
 p
la
te
le
ts
 (
/µ
l)
28
 0
00
0
0
0
27
 0
00
20
 0
00
37
 0
00
N
um
be
r 
of
 p
la
te
le
ts
 
at
 b
eg
in
ni
ng
 o
f 
IV
IG
 (
/µ
l)
25
3 
00
0
15
6 
00
0
13
3 
00
0
15
 0
00
27
 0
00
87
 0
00
12
6 
00
0
M
ea
n 
do
se
 o
f 
IV
IG
 
(g
/k
g 
b.
w
./m
on
th
)
0.
43
-0
.3
8
0.
36
-0
.4
5
0.
35
-0
.4
2
0.
35
-0
.4
5
0.
38
-0
.3
0.
4-
0.
35
0.
42
-0
.5
0
M
ea
n 
nu
m
be
r 
of
 p
la
te
le
ts
 
du
ri
ng
 
IV
IG
 (
/µ
l)
 (
ra
ng
e)
14
9 
10
0
(1
20
 0
00
-1
96
 0
00
)
12
3 
00
0 
(5
7 
00
0-
19
8 
00
0)
13
1 
00
0 
(9
7 
00
0-
15
4 
00
0)
51
 4
60
 (
18
 0
00
-6
8 
00
0)
11
3 
50
0 
(5
6 
00
0-
15
4 
00
0)
17
2 
40
0 
(9
9 
00
0-
26
4 
00
0)
11
2 
70
0 
(8
6 
00
0-
13
3 
00
0)
E
pi
so
de
s 
of
 e
xa
ce
rb
at
io
ns
 
of
 t
hr
om
bo
cy
to
pa
en
ia
 
du
ri
ng
 I
V
IG
1
0
3 
(1
 s
ev
er
e)
4
1 
se
ve
re
0
0
T
he
ra
py
 o
f 
th
ro
m
bo
cy
to
pa
en
ia
 
ex
ac
er
ba
ti
on
s
IV
IG
 1
.0
 g
/k
g 
b.
w
. s
te
ro
id
s
st
er
oi
ds
, p
la
te
le
ts
, 
er
yt
hr
oc
yt
es
 a
nd
 
pl
as
m
a 
tr
an
sf
us
io
ns
, 
pl
as
m
ap
he
re
si
s
IV
IG
 1
.0
 g
/k
g 
b.
w
st
er
oi
ds
, 
sp
le
ne
ct
om
y
T
im
e 
of
 o
bs
er
va
ti
on
12
 y
ea
rs
2 
ye
ar
s
7 
ye
ar
s
4 
ye
ar
s
5 
ye
ar
s
4 
ye
ar
s
11
 y
ea
rs
Central European Journal of Immunology 2015; 40(1)
Thrombocytopenia in common variable immunodeficiency patients – clinical course, management, and effect of immunoglobulins
87
Methods
The following assays were used for patients at least 
twice, before the establishing the diagnosis and during 
the substitution of immunoglobulins. The level of immu-
noglobulins (IgG, IgA, IgM) in serum were assayed with 
nephelometry using the paediatric level of sensitivity. The 
percentage of T, B lymphocytes and NK cells within lym-
phocytes were assayed with flow cytometry followed by 
recalculation of the number per µl based on total white 
blood cells count from the same sample. The flow cy-
tometry assay included the T cell subpopulations ratio 
(CD4:CD8, TCR a/b : TCR g/d), and the percentage and 
number of activated T cells (CD3/HLA-DR). The response 
of lymphocytes to stimulation was tested in three-day cul-
ture (PHA, CD3, and PWM) and seven-day culture (PPD, 
Candida) ending with H3-thymidine uptake. The borderline 
value of the stimulation index was 20. The response to 
vaccines was assayed with anti-HBs, anti-rubeola, anti-tet-
anus, anti-bordetella, and anti- Streptococcus pneumoniae 
antibodies (if the child was vaccinated for this antigen). 
Moreover, the antibodies for CMV and EBV antigens were 
tested as common viral antigens.
The number and mean volume of platelets, and other 
parameters of morphology were checked on every visit as-
sociated with infusion of immunoglobulins, and in mean-
time if necessary. In all patients with thrombocytopaenia, 
the presence of autoantibodies (antinuclear standard panel 
with fluorescent microscopy) was assayed. The volume 
of platelets was normal in all of our patients (WAS syn-
drome exclusion). Other tests (biochemistry, microbiology, 
virusology, Coomb’s test) and analyses were performed 
according to individual symptoms in patients [e.g. ultraso-
nography (USG), computed tomography (CT), magnetic 
resonance imaging (MRI), high-resolution computed to-
mography (HRCT) of lungs, spirometry].
Results
The onset of thrombocytopaenia in patients 1 to 6 was 
acute, mainly associated with infections, and the last pa-
tient (number 7) developed thrombocytopaenia in chronic 
form without acute episodes (Tables 1, 2).
In patient 1 thrombocytopaenia occurred after a short, 
mild viral infection during regular substitution of IVIG 
because of diagnosis of CVID [lymphadenopathy, sple-
nomegaly, low number of T lymphocytes (348/µl), low 
number of B lymphocytes (124/µl)]. This patient was 
additionally diagnosed for ALPS (autoimmune lymph-
oproliferative disease), but the apoptosis was normal, so 
ALPS was excluded. The most probable explanation for 
leukopaenia and lymphopaenia despite thrombocytopae-
nia was spleen hyperactivity. On regular substitution in 
the replacing dose, the level of IgG was from 5.36 g/l to 
7.7 g/l, which was within the normal range for the patient’s 
age. However, the patient developed an adverse reaction 
to immunoglobulin preparation. Changing the product 
was enough to prevent this reaction in the following infu-
sions. The number of T and B lymphocytes was still be-
low the lower limit of normal value for age. The episode 
of acute thrombocytopaenia occurred during a mild viral 
infection (lowest platelets number – 28 000/µl). The ef-
fect of IVIG used in high dose (2 × 1.0 g/kg b.w.) in this 
episode of thrombocytopaenia was transient, and steroids 
(dexamethasone pulses followed by regular oral steroid 
therapy) were used for four months. After this therapy the 
number of platelets was within the normal range. During 
the following four years of continued regular substitution 
(subcutaneous form) the number of platelets was between 
120 000/µl and 196 000/µl without decrease, despite infec-
tions (mainly viral with mild clinical course).
Patient 2 was treated with immunoglobulins in high 
dose because of acute thrombocytopaenia and leukopae-
nia (lack of platelets and 2800/µl of leukocytes) prior 
to diagnosis of CVID. The effect of steroids was short 
(2-3 days) despite a high dose (pulses of dexamethasone), 
and therapy with azathioprine was introduced. The throm-
bocytopaenia slowly resolved during three months. The 
therapy with steroid and azathioprine was stopped. After 
two following years without episodes of thrombocytopae-
nia, during a prolonged infection of the respiratory tract 
hypogammaglobulinaemia was noted with low number of 
T lymphocytes (997/µl) and NK cells (65/µl), and a lack 
of B lymphocytes (20/µl). The splenomegaly, leukopaenia 
and lymphadenopathy (localised in lungs hilus), and de-
crease of platelet number to 57 000/µl developed in the last 
year of observation, despite regular substitution of immu-
noglobulins in a dose of 0.45-0.6 g/kg b.w. every month. 
Regular substitution resulted in a decreased number of in-
fections, milder course, and better response to therapy with 
antibiotics. The IgG level was below 5.0 g/l despite higher 
doses of immunoglobulins in infusions, which suggested 
another process of loss or process of tissue binding immu-
noglobulins. The additional tests for ALPS were performed 
because of progressing splenomegaly, lymphadenopathy, 
thrombocytopaenia, and leukopaenia. The number of DNT 
a/b lymphocytes was below 2%, which excluded this di-
agnosis. There were no symptoms or laboratory data sug-
gesting protein loss enteropathy. In the last month, a lung 
biopsy was performed due to disseminated non-inflamma-
tory consolidations of lung tissue, implying lymphocyte 
interstitial pneumonia (LIP) with typical infiltrates. After 
high-dose steroid therapy for two weeks, followed by main-
tenance dose of steroids, the LIP symptoms resolved and 
the mean level of IgG increased to above 6.0 g/l.
In patient 3 low levels of IgG and IgA, low number 
of T lymphocytes, and recurrent infections were observed 
since 3.5 years of life, but the substitution of IgG was de-
layed until the 4th year of life (overlapping THI and CVID 
symptoms). The response of lymphocytes to stimulation 
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was poor (indexes 1-5), which suggested a diagnosis of 
CVID. After the episode of acute thrombocytopaenia treat-
ed with steroids, the stabilisation of platelets was obtained 
with azathioprine use for a prolonged period (nine months) 
concurrent with IVIG introduced due to established diag-
nosis of CVID. The number of platelets in this time was 
between 95 000/µl and 147 000/µl, and the dose of im-
munoglobulins was 0.6 g/kg b.w. because of persistent 
leukopaenia (2100-3500/µl). Two months after cessation 
of azathioprine therapy, severe, life-threatening thrombo-
cytopaenia (platelets nadir – 16 000/µl) and haemolytic 
anaemia (erythrocytes – 1.7 mln/µl) with anti-erythrocyte 
antibodies (direct Coomb’s positive test) was seen. The 
patient was treated with steroids (high-dose pulses), plate-
let and erythrocyte transfusions, and immunoglobulins in 
high dose (2.0 g/kg b.w./3 days infusion) with transient 
improvement of clinical symptoms. The plasmapheresis 
was followed by a high dose of immunoglobulins and 
steroids for a prolonged period (six months), which was 
effective. The regular substitution of immunoglobulins in 
a replacing dose was continued in the patient with leu-
kopaenia, stable number of platelets (86 000-168 000/µl), 
and splenomegaly. The diagnosis was changed to Evans 
syndrome in CVID. Now, three years later, the patient is 
without substitution of immunoglobulins but under haema-
tological control without episodes of thrombocytopaenia 
(platelet count 120 000-183 000/µl).
The first episode of thrombocytopaenia occurred in 
a 10-year-old girl (patient 4) after viral infection. Therapy 
with steroids (pulses of dexamethasone) was effective, but 
the number of platelets was steroid dependent, so the dose 
of steroids was high and used for a prolonged time. Af-
ter two years of such therapy the number of platelets was 
within normal range, but diabetes and overweight were 
noted as side effects of prolonged steroid therapy. The di-
agnosis of CVID was made two years after the first episode 
of thrombocytopaenia. Hypogammaglobulinaemia (IgG 
and IgM), low number of T and B lymphocytes (820/µl 
and 138/µl, respectively), few NK cells (16/µl), leukopae-
nia (2600/µl), and mainly neutropaenia were indications 
for regular substitution of immunoglobulins in a replac-
ing dose. The number of platelets was checked every two 
weeks, and the next episode of thrombocytopaenia was 
noted two months after the beginning of immunoglobulin 
substitution. This episode of severe thrombocytopaenia 
(8000/µl platelets) and the next three episodes were treated 
only with high doses of immunoglobulins (2.0 g/kg b.w./ 
3 days infusion), but the effect was transient and unsatis-
factory. Steroids were not used due to severe side effects 
after the previous therapy. The leukopaenia (number of 
leukocytes was from 1200 to 3800/µl), low number of 
lymphocytes T (490/µl), B (105/µl), and NK cells (98/µl), 
and chronic thrombocytopaenia (mean number of plate-
lets was about 50 000/µl) were noted during the next four 
years of regular substitution of immunoglobulins, despite 
a single episode of mild infection. Last year a high level 
of antibodies to thyroid peroxidase was detected followed 
by thyroid hormone supplementation due to subclinical hy-
pothyreosis. The number of platelets is still below normal 
value without diathesis, with present obesity and normal 
glucose level.
Patient 5 was diagnosed with CVID before the onset of 
thrombocytopaenia. The first episode of thrombocytopae-
nia occurred despite regular immunoglobulin substitution 
(intravenous 0.42 g/kg b.w.). Therapy included only ster-
oids, and a slow increase of platelet count was observed 
within two months (from 27 000/µl to 44 000/µl). In next 
one and a half years, the numbers of platelets (about 
120 000/µl) and leukocytes (3500-4100/µl) were stable, and 
the regular substitution of immunoglobulins in a replacing 
dose was continued. The mild viral infection induced se-
vere exacerbation of thrombocytopaenia and was treated 
with steroids (dexamethasone in pulses). The platelet num-
ber was unstable, and after eight months of therapy with 
steroids and immunoglobulins in high dose (1.0-2.0 g/kg 
b.w.), the decision to perform splenectomy was made by 
a haematologist. After this surgery the platelet count was 
409 000/µl and the boy was excluded from further obser-
vation. Due to CVID diagnosis the substitution of immu-
noglobulins is continued in subcutaneous form.
Patient 6 was diagnosed with CVID after the first epi-
sode of thrombocytopaenia treated with steroids. Hypog-
ammaglobulinaemia (IgG and IgA) and infections of the 
respiratory tract were noted as symptoms of immunodefi-
ciency. The number of leukocytes, lymphocytes, subpop-
ulations of T lymphocytes, B lymphocytes, and NK cells 
were within normal range for age. The number of platelets 
was 87 000/µl at the beginning of regular substitution be-
cause of CVID. In the following three years of regular sub-
stitution of immunoglobulins, the number of platelets was 
stable, slowly increasing to 264 000/µl, without exacerba-
tions, despite respiratory tract infections. Stable level of 
immunoglobulins, few infections with mild clinical course, 
and good response to therapy led us to finish the regular 
substitution. The patient was offered immunoglobulin infu-
sion as supportive therapy during severe infection but until 
now (six more years of observation) he has not required it.
Patient 7 was diagnosed with CVID in the fifth year of 
life after hypogammaglobulinaemia during first four years 
of life, diagnosed as transient hypogammaglobulinaemia 
of infancy (THI). Infusions of immunoglobulins were in-
dicated as supportive therapy for episodes of pneumonia, 
but there were no indications for regular substitution due 
to THI. The clinical symptoms of CVID at diagnosis in-
cluded lymphadenopathy, splenomegaly (“megaspleen”), 
hypogammaglobulinaemia (IgG, lack of IgA), and leuko-
paenia with low number of T and B lymphocytes in this 
patient. Moreover, this boy was born with one kidney. The 
regular substitution of immunoglobulins introduced after 
CVID diagnosis helped decrease the number of respira-
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tory tract infections. In gteh following years bronchiec-
tases and progressing fibrosis with lymphocyte infiltration 
(lymphocytic interstitial pneumonia – LIP) developed. Af-
ter two years of immunosuppressive therapy with steroids 
to inhibit the progress of lung fibrosis and lymphocytic 
infiltrates, severe adverse reactions to steroids (osteopo-
rosis, overweight, inhibition of growth) were observed 
without any visible inhibitory effect on the fibrotic pro-
cess. The positive effect of steroid therapy was resolving 
of LIP symptoms (checked with lung biopsy). The number 
of platelets and leukocytes were stable, close to the lower 
limit of normal value. The next therapy with azathioprine 
was administered in the hope of inhibiting the progress of 
lung fibrosis, but the response to this therapy was poor. 
Moreover, as a side effect of this immunosuppression, the 
number of platelets dropped below 100 000/µl and leu-
kopaenia with low number of T and B lymphocytes, and 
lack of NK cells were noted within one year. The fibrosis 
of lungs is progressing slowly, but kidney insufficiency is 
now a clinical problem. The therapy with azathioprine was 
stopped. The number of platelets is still below 100 000/µl, 
leukocytes below 3000/µl, but the bone marrow is normal 
with rich cellularity and proper representation of myeloid 
and lymphoid ontogeny. The persistent leukopaenia, mild 
thrombocytopaenia, megaspleen, and lung fibrosis are still 
indications for suppression, but the kidney insufficiency 
(progressing) and severe side effect are limitations for such 
therapy. Now, the patient is under careful clinical control 
with symptomatic and supportive therapy for lung function 
and regular substitution of immunoglobulins (up to 0.5 g/
kg b.w. subcutaneously). The prognosis for this patient is 
poor due to clinical symptoms and increasing laboratory 
parameters of lung and kidney insufficiency.
Discussion
Thrombocytopaenia associated with immunodeficiency 
presented two forms – episodes of acute thrombocytopae-
nia, alone or as a part of Evans syndrome with remission 
(normal number of platelets), and chronic thrombocyto-
paenia with platelet count always below normal level [7, 
11]. In our group of CVID patients with thrombocytopae-
nia these (recurrent acute or chronic) forms of thrombo-
cytopaenia were noted without relation to time of CVID 
diagnosis. Regular intravenous substitution of immuno-
globulins in the CVID patients for exacerbation of chronic 
thrombocytopaenia or episodes of acute thrombocytopae-
nia were not effective. Routine therapy with steroids and 
high doses of immunoglobulins was necessary and was 
used with success despite regular immunoglobulin sub-
stitutions before the episode. After infusion of immuno-
globulins in high dose, in remission of thrombocytopaenia, 
the regular substitution was continued. However, there are 
problems of thrombocytopaenia in CVID – short effect 
of high-dose immunoglobulin therapy and indication for 
maintenance e.g. steroid therapy to support the remission, 
or chronic thrombocytopaenia after short remission with 
normal number of platelets. If the therapy with high-dose 
immunoglobulins and/or steroids is effective, the remission 
with normal number of platelets in some CVID patients 
is long lasting, similarly to children without CVID. The 
second group of patients demonstrated chronic thrombo-
cytopaenia with the number of platelets below 100 000/
µl, and this level of platelets seemed to be stable during 
regular substitution of immunoglobulins in replacing dos-
es. These patients did not require additional therapy with 
steroids or azathioprine as long as the number of plate-
lets decreased and the clinical symptoms of thrombocy-
topaenia occurred. A large decrease in platelet count with 
life-threatening clinical symptoms or refractory, severe 
thrombocytopaenia are always indications for splenectomy 
without regard to CVID diagnosis [7, 10, 11]. Moreover, 
in CVID patients the refractory thrombocytopaenia seemed 
to be more frequent with a higher ratio of indications for 
splenectomy than in otherwise healthy children. In chronic 
thrombocytopaenia regular substitution of immunoglobu-
lins in the replacing dose seemed to stabilise the platelets 
count, particularly in intravenous form of substitution. 
Clinical observations of our two patients with chronic 
thrombocytopaenia showed increased platelet count only 
for a few days after infusion of immunoglobulins, followed 
by a slow decrease during the following three weeks, but 
the level was still higher than in acute episodes. This sta-
ble, safe level of platelets meant that the patients lived with 
immunoglobulin substitution without additional therapy of 
thrombocytopaenia. Some of these patients with CVID and 
thrombocytopaenia demonstrate persistent leukopaenia. 
The intravenous regular immunoglobulin substitution in 
a replacing dose and the trough level of IgG have no effect 
on the white blood cell count in these patients. However, 
this leukopaenia is mild in the majority of patients, and 
additional therapy is needed in singular cases only.
The autoimmunity symptoms observed in CVID pa-
tients are often overlapping, which is an indication for 
additional diagnosis of WAS, ALPS syndrome, or rare 
complications of CVID, such as GLILD (granulomatous 
and lymphocytes interstitial lung disease) or protein loss 
enteropathy due to atypical celiac or other inflammatory 
bowel diseases (e.g. Leśniowski-Crohn’s disease). These 
autoimmune syndromes associated with CVID are more 
difficult to diagnose and require more aggressive therapy 
due to atypical clinical course and therapy resistance.
Conclusions
Regular infusion of immunoglobulins in replacing dos-
es is a good supportive therapy in chronic thrombocytopae-
nia associated with CVID.
Regular substitution of immunoglobulins in a replac-
ing dose does not prevent the occurrence of autoimmune 
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thrombocytopaenia and exacerbations of chronic thrombo-
cytopaenia in CVID.
In episodes of acute thrombocytopaenia or exacerba-
tions of chronic thrombocytopaenia, infusions of immuno-
globulins in high dose are effective, despite previous reg-
ular substitution of immunoglobulins in a replacing dose.
The authors declare no conflict of interest.
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